Gilead Sciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gilead Sciences Inc (GILD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gilead Sciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 30,988M vs 434,312M combined for its competitors (6.7% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.1% annualized vs trailing 12 months), vs accelerating (+7.1%) for its tracked peer group.
- Growth: Gilead Sciences Inc generated 6.8% revenue growth year over year in Q3 2026, vs 13.9% for its competitors combined.
- Profitability: Its 29.3% net margin compares with 15.5% for the peer group.
- Scale: Gilead Sciences Inc ranks #2 of 165 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 21.6% of industry market cap.
- Peer revenue share: Gilead Sciences Inc accounted for 6.7% of combined revenue among its tracked peer group, down from 7.1% a year earlier.
- Peer differentiation: Revenue per employee of $1.82M compares with $0.94M for the peer group (1.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GILD Sales vs. its Competitors, Q3 2026
Gilead Sciences Inc reported revenue growth of 6.83 % year on year in Q3 2026, below its competitors' combined revenue growth of 13.89 %.
With a net margin of 29.27 %, Gilead Sciences Inc achieved higher profitability than its competitors (15.50 %).
Gilead Sciences Inc generated 6.66 % of the combined sales of its peer group, down from 7.07 % a year earlier.
API endpoints for this dataset
Gilead Sciences Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Gilead Sciences Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Gilead Sciences Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Gilead Sciences Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (15) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Gilead Sciences Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.7% year over year, combined, vs 6.8% for Gilead Sciences Inc. Gilead Sciences Inc's share of combined industry revenue moved from 20.93% to 18.37%, a loss of 2.56 percentage points.
Gilead Sciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gilead Sciences Inc | No | Yes | No | No |
| Competitors combined (214) | ||||
| High-Confidence Competitors (61) | ||||
| Similar-Size Competitors (6) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 75.00 % (6 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GILD Stock Performance relative to its Competitors
GILD Stock Performance relative to High-Confidence Competitors
GILD Stock Performance relative to Similar-Size Competitors
GILD Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cidara Therapeutics Inc | 282.9% | Outperformed |
| 2 | Jasper Therapeutics Inc | 282.9% | Outperformed |
| 3 | Gt Biopharma Inc | 282.9% | Outperformed |
| 4 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 5 | An2 Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Gilead Sciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Gilead Sciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Gilead Sciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Gilead Sciences Inc |
211,819.32 | 30,988.00 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Beone Medicines Ltd |
628,232.68 | 6,128.24 |
 Abbvie Inc |
519,727.60 | 66,014.00 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
| SUBTOTAL | 5,854,272.00 | 842,497.15 |
Sign in to see all competitors of Gilead Sciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Gilead Sciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Gilead Sciences Inc's Competitors Named by the Company
Competitive relationships identified from Gilead Sciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Autolus Therapeutics Plc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Aptevo Therapeutics Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Kymera Therapeutics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Tevogen Bio Holdings Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Pyxis Oncology Inc | Company report | 85% |
| Alfasigma S.p.A. | Company report | 85% |
| ENTO | Company report | 85% |
| Eiger Biopharmaceuticals Inc | Company report | 85% |
| Intercept Pharmaceuticals | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Gridai Technologies Corp | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| PHGEU | Company report | 85% |
| Genfit S a | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Biomx Inc | Company report | 85% |
| GLTO | Company report | 85% |
| Damora Therapeutics Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| RENB | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Cocrystal Pharma Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Exelixis Inc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Sanofi | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Chimerix Inc | Company report | 85% |
| Sorrento Therapeutics Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viking Therapeutics Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Iteos Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Aligos Therapeutics Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Atea Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Gilead Sciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Gilead Sciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Gilead Sciences Inc .
Gilead Sciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Gilead Sciences Inc | 211,819 | 1,822,824 | -227,235 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Beone Medicines Ltd | 628,233 | 510,686 | 54,642 |
| Abbvie Inc | 519,728 | 1,158,140 | 181,509 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| PEERS TOTAL | 5,642,453 | 939,943 | 137,567 |
Sign in to see all peers for Gilead Sciences Inc .
Gilead Sciences Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Gilead Sciences Inc .
Gilead Sciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Gilead Sciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Gilead Sciences Inc ranks #2 of 158 companies by market capitalization in its industry, holding 21.61 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,350, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 248,369 | 25.79 % |
| 2 | Gilead Sciences Inc | 208,103 | 21.61 % |
| 3 | Moderna Inc | 103,912 | 10.79 % |
| 4 | Argenx Se | 61,963 | 6.43 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Gilead Sciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Gilead Sciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Amgen Inc | 248,369 | 44.67 % |
| 2 | Gilead Sciences Inc | 208,103 | 35.67 % |
| 3 | Moderna Inc | 103,912 | 973.10 % |
| 4 | Argenx Se | 1,234 | 12.3% |
| 5 | Revolution Medicines Inc | 1,234 | 12.3% |
| 6 | Biogen Inc | 1,234 | 12.3% |
| 7 | Biontech Se | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Gilead Sciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Gilead Sciences Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 79.93 % | 35.08 % (avg) | +44.9 pp |
| Operating Margin | -7.62 % | industry median | -20.7 pp |
| EBITDA Margin | 2.43 % | -1.18 % (avg) | +3.6 pp |
| Capital Intensity (Capex / Revenue) | 2.26 % | 8.43 % (avg) | -6.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Gilead Sciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | 268.1x | 16.7x | +251.5x |
| P/B | 9.9x | 5.1x | +4.8x |
| Return on Equity | -21.79 % | industry aggregate | -15.72 % |
| Return on Invested Capital | -3.89 % | -10.91 % (avg) | 7.02 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Gilead Sciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -15.24 % | 1.46 % | 9.98 % | 10.60 % | -0.09 % | -0.60 % | 6.04 % | 2.40 % |
| Operating Margin | 37.06 % | 19.10 % | 16.49 % | 36.32 % | 26.87 % | 28.05 % | 5.78 % | 34.04 % |
| Return on Invested Capital | 10.80 % | 5.76 % | 5.80 % | 12.80 % | 10.03 % | 10.75 % | 2.73 % | 15.45 % |
| P/E | 16.3x | 15.6x | 812.4x | 14.2x | 23.3x | 17.3x | 243.3x | 17.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Gilead Sciences Inc's Strategic Group Map
Gilead Sciences Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Gilead Sciences Inc's trailing-12-month revenue growth of 6.5% and operating margin of -7.6% compares with an average of 7.5% growth and -2.7% margin across its 8 closest peers by combined growth, margin and ROIC -- Gilead Sciences Inc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Gilead Sciences Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Gilead Sciences Inc falls in the Dog quadrant: relative market share of 0.84x vs its largest competitor, in an industry growing revenue 9.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Gilead Sciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,350 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.26 % vs industry average 8.43 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Gilead Sciences Inc's dedicated Suppliers and Customers pages, not here.
Gilead Sciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Gilead Sciences Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Gilead Sciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+7.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 20.7 points below the industry median.
- Return on equity 15.7 points below the industry aggregate.
Opportunities
- A meaningful share of competitors (55.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Losing revenue share to the broader industry (-2.6 points over the past year).
Methodology: see Methodology: SWOT Analysis.
Gilead Sciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Gilead Sciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Gilead Sciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +11.7 % | +0.1 % |
Sign in to see all peers for Gilead Sciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Gilead Sciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Gilead Sciences Inc .
Gilead Sciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Gilead Sciences Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Gilead Sciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Gilead Sciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Gilead Sciences Inc | - | 6.84 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Johnson and Johnson | 42.68 | 6.95 |
| Beone Medicines Ltd | 948.48 | 102.51 |
| Abbvie Inc | 50.48 | 7.87 |
| Merck and Co Inc | 119.93 | 5.52 |
| PEERS AVERAGE | 50.95 | 6.95 |
Sign in to see all peers for Gilead Sciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.